SUMMARY Two patients with neonatal Graves's disease are reported. One of them had a delayed onset because of suppression of the fetal thyroid gland by antithyroid drug taken by the mother during pregnancy. Thyroid-stimulating immunoglobulins (TSAb), measured by a receptor assay, were present in both babies when they were thyrotoxic, and also in their mothers. TSAb was noted and the eye signs regressed. The baby remained asymptomatic after the antithyroid drugs were stopped at 13 weeks. Both the mother and the baby defaulted from follow-up until the baby was 1-year old although the mother sought treatment from private practitioners. Case 2. The mother had received radioactive iodine therapy for thyrotoxicosis 1 year before delivery of the baby. In the 35th week of pregnancy, she relapsed again but no treatment was given.
A girl was delivered during the 43rd week of pregnancy, birthweight 2300 g. On day 2, she began to manifest hyperthyroid features with irritability, sweating, and tachycardia. Thyroid function tests on day 4 confirmed hyperthyroidism (Table 2 ).
There was a good response to carbimazole and potassium iodide which were stopped after 6 weeks and the baby remained euthyroid thereafter. Methods Serum thyroxine was measured by Thyopac-4 kit (Amersham), thyroid hormine binding capacity by Thyopac-3 kit (Amersham), and free thyroxine index calculated from these values.
TSAb activity was measured by a receptor assay4 TSAb-negative. The intra-assay and interassay coefficients of variation were 5 % and 12% respectively. In particular, we have found the TSAb indices in 10 normal women 6 weeks' postpartum to range from 99 * 7 to 119 * 6 % (mean 109 * 9 %) and in 9 euthyroid 1-year-old babies to range from 84 2 to 128*4% (mean 98*6y%).
Results
The thyroid function tests and TSAb indices of Case 1 and the maternal TSAb indices are shown in 4 . On day 25 when the baby was still receiving antithyroid drugs, the TSAb index was positive at 62 6% and the corresponding TSAb index in the mother was also positive at 61-8 %. At I year of age, the TSAb index in the baby was negative at 91%.
Discussion
Two patients with neonatal Graves's disease are reported. In Case 1, the clinical manifestations were delayed probably due to the late withdrawal of antithyroid drug in the pregnant mother so that the thyroid gland was suppressed in utero and during the baby's first few weeks of life. In Case 2, thyrotoxicosis was evident almost from birth, probably because no antithyroid drug had been given to the mother during pregnancy.
In both cases, TSAb were positive in the babies who still required drugs for the thyrotoxicosis. TSAb were also positive in their mothers at the same time. This is in keeping with the hypothesis that maternal TSAb cross the placenta and are responsible for the manifestations of neonatal Graves's disease. It is interesting to note that TSAb could still be detected in Case 1 as late as 7 weeks of life. TSAb were not detectable at 1 year of age in either baby when each was euthyroid without any treatment.
